3,388
Views
0
CrossRef citations to date
0
Altmetric
Review Article

Obesity and menopause

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon
Article: 2312885 | Received 12 Dec 2023, Accepted 25 Jan 2024, Published online: 11 Feb 2024

References

  • Chater A. Obesity. Psychological perspectives on obesity: policy, practice and research priorities. The British Psychological Society. 2020 May 7. Available from: https://www.bps.org.uk/blog/psychological-perspectives-obesity-policy-practice-and-research-priorities
  • Leeners B, Geary N, Tobler PN, et al. Ovarian hormones and obesity. Hum Reprod Update. 2017;23(3):1–6. doi:10.1093/humupd/dmw045.
  • World Health Organization. Obesity and overweight. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
  • Wharton S, Lau DCW, Vallis M, et al. Obesity in adults: a clinical practice guideline. CMAJ. 2020;192(31):E875–E891. doi:10.1503/cmaj.191707.
  • Palacios S. Obesity in women’s life: role of GLP-1 agonists. Gynecol Endocrinol. 2022;38(11):889–890. doi:10.1080/09513590.2022.2163235.
  • Wichmann IA, Cuello MA. Obesity and gynecological cancers: a toxic relationship. Int J Gynaecol Obstet. 2021;155(Suppl 1):123–134. doi:10.1002/ijgo.13870.
  • Nappi RE, Chedraui P, Lambrinoudaki I, et al. Menopause: a cardiometabolic transition. Lancet Diabetes Endocrinol. 2022;10(6):442–456. doi:10.1016/S2213-8587(22)00076-6.
  • Mauvais-Jarvis F, Clegg DJ, Hevener AL. The role of estrogens in control of energy balance and glucose homeostasis. Endocr Rev. 2013;34(3):309–338. doi:10.1210/er.2012-1055.
  • Kohrt WM, Wierman ME. Preventing fat gain by blocking Follicle-Stimulating hormone. N Engl J Med. 2017;377(3):293–295. doi:10.1056/NEJMcibr1704542.
  • Van Pelt RE, Gavin KM, Kohrt WM. Regulation of body composition and bioenergetics by estrogens. Endocrinol Metab Clin North Am. 2015;44(3):663–676. doi:10.1016/j.ecl.2015.05.011.
  • Hodson L, Harnden K, Banerjee R, et al. Lower resting and total energy expenditure in postmenopausal compared with premenopausal women matched for abdominal obesity. J Nutr Sci. 2014;3:e3. doi:10.1017/jns.2013.38.
  • Lovejoy JC, Champagne CM, de Jonge L, et al. Increased visceral fat and decreased energy expenditure during the menopausal transition. Int J Obes (Lond). 2008;32(6):949–958. doi:10.1038/ijo.2008.25.
  • Melanson EL, Gavin KM, Shea KL, et al. Regulation of energy expenditure by estradiol in premenopausal women. J Appl Physiol (1985). 2015;119(9):975–981. doi:10.1152/japplphysiol.00473.2015.
  • Shea KL, Gavin KM, Melanson EL, et al. Body composition and bone mineral density after ovarian hormone suppression with or without estradiol treatment. Menopause. 2015;22(10):1045–1052. doi:10.1097/GME.0000000000000430.
  • Sowers M, Zheng H, Tomey K, et al. Changes in body composition in women over six years at midlife: ovarian and chronological aging. J Clin Endocrinol Metab. 2007;92(3):895–901. doi:10.1210/jc.2006-1393.
  • Davies KM, Heaney RP, Recker RR, et al. Hormones, weight change and menopause. Int J Obes Relat Metab Disord. 2001;25(6):874–879. doi:10.1038/sj.ijo.0801593.
  • Guthrie JR, Dennerstein L, Dudley EC. Weight gain and the menopause: a 5-year prospective study. Climacteric. 1999;2(3):205–211. doi:10.3109/13697139909038063.
  • Wing RR, Matthews KA, Kuller LH, et al. Weight gain at the time of menopause. Arch Intern Med. 1991;151(1):97–102. doi:10.1001/archinte.1991.00400010111016.
  • Crawford SL, Casey VA, Avis NE, et al. A longitudinal study of weight and the menopause transition: results from the Massachusetts women’s health study. Menopause. 2000;7(2):96–104. doi:10.1097/00042192-200007020-00005.
  • Blümel JE, Castelo-Branco C, Rocangliolo ME, et al. Changes in body mass index around menopause: a population study of Chilean woman. Menopause. 2001;8(4):239–244. doi:10.1097/00042192-200107000-00004.
  • Sternfeld B, Wang H, Quesenberry CP, Jr, et al. Physical activity and changes in weight and waist circumference in midlife women: findings from the study of women’s health across the nation. Am J Epidemiol. 2004;160(9):912–922. doi:10.1093/aje/kwh299.
  • Ho SC, Wu S, Chan SG, et al. Menopausal transition and changes of body composition: a prospective study in chinese perimenopausal women. Int J Obes (Lond). 2010;34(8):1265–1274. doi:10.1038/ijo.2010.33.
  • Sornay-Rendu E, Karras-Guillibert C, Munoz F, et al. Age determines longitudinal changes in body composition better than menopausal and bone status: the OFELY study. J Bone Miner Res. 2012;27(3):628–636. doi:10.1002/jbmr.1469.
  • Abdulnour J, Doucet E, Brochu M, et al. The effect of the menopausal transition on body composition and cardiometabolic risk factors: a Montreal-Ottawa new emerging team group study. Menopause. 2012;19(7):760–767. doi:10.1097/gme.0b013e318240f6f3.
  • Wells JC. Commentary: the paradox of body mass index in obesity assessment: not a good index of adiposity, but not a bad index of cardio-metabolic risk. Int J Epidemiol. 2014;43(3):672–674. doi:10.1093/ije/dyu060.
  • Müller MJ, Lagerpusch M, Enderle J, et al. Beyond the body mass index: tracking body composition in the pathogenesis of obesity and the metabolic syndrome. Obes Rev. 2012;13(Suppl 2):6–13. doi:10.1111/j.1467-789X.2012.01033.x.
  • Rubin R. Postmenopausal women with a "normal" BMI might be overweight or even obese. JAMA. 2018;319(12):1185–1187. doi:10.1001/jama.2018.0423.
  • Christiansen MR, Kilpeläinen TO, McCaffery JM. Abdominal obesity genetic variants predict waist circumference regain after weight loss. Diabetes. 2023;72(10):1424–1432. doi:10.2337/db23-0131.
  • Cienfuegos S, Gabel K, Kalam F, et al. Changes in body weight and metabolic risk during time restricted feeding in premenopausal versus postmenopausal women. Exp Gerontol. 2021;154:111545. doi:10.1016/j.exger.2021.111545.
  • Freeman EW, Sammel MD, Lin H, et al. Obesity and reproductive hormone levels in the transition to menopause. Menopause. 2010;17(4):718–726. doi:10.1097/gme.0b013e3181cec85d.
  • Davis SR, Castelo-Branco C, Chedraui P, et al. Writing group of the international menopause society for world menopause day 2012. Understanding weight gain at menopause. Climacteric. 2012;15(5):419–429. doi:10.3109/13697137.2012.707385.
  • Thurston RC, Santoro N, Matthews KA. Adiposity and hot flashes in midlife women: a modifying role of age. J Clin Endocrinol Metab. 2011;96(10):E1588–1595. doi:10.1210/jc.2011-1082.
  • Thurston RC, Sowers MR, Chang Y, et al. Adiposity and reporting of vasomotor symptoms among midlife women: the study of women’s health across the nation. Am J Epidemiol. 2008;167(1):78–85. doi:10.1093/aje/kwm244.
  • Zhu D, Chung HF, Pandeya N, et al. Body mass index and age at natural menopause: an international pooled analysis of 11 prospective studies. Eur J Epidemiol. 2018;33(8):699–710. doi:10.1007/s10654-018-0367-y.
  • Szegda KL, Whitcomb BW, Purdue-Smithe AC, et al. Adult adiposity and risk of early menopause. Hum Reprod. 2017;32(12):2522–2531. doi:10.1093/humrep/dex304.
  • Moslehi N, Shab-Bidar S, Ramezani Tehrani F, et al. Is ovarian reserve associated with body mass index and obesity in reproductive aged women? A meta-analysis. Menopause. 2018;25(9):1046–1055. doi:10.1097/GME.0000000000001116.
  • Francis EC, Oken E, Hivert MF, et al. Anti-Müllerian hormone and adiposity across mid-life among women in project viva. Menopause. 2023;30(3):247–253. doi:10.1097/GME.0000000000002143.
  • Navarro VM. Interactions between kisspeptins and neurokinin B. Adv Exp Med Biol. 2013;784:325–347. doi:10.1007/978-1-4614-6199-9_15.
  • Da Fonseca AM, Bagnoli VR, Souza MA, et al. Impact of age and body mass on the intensity of menopausal symptoms in 5968 Brazilian women. Gynecol Endocrinol. 2013;29(2):116–118. doi:10.3109/09513590.2012.730570.
  • Yokota M, Makita K, Hirasawa A, et al. Symptoms and effects of physical factors in Japanese middle-aged women. Menopause. 2016;23(9):974–983. doi:10.1097/GME.0000000000000660.
  • Thurston RC, Chang Y, Mancuso P, et al. Adipokines, adiposity, and vasomotor symptoms during the menopause transition: findings from the study of women’s health across the nation. Fertil Steril. 2013;100(3):793–800. doi:10.1016/j.fertnstert.2013.05.005.
  • Gold EB, Crawford SL, Shelton JF, et al. Longitudinal analysis of changes in weight and waist circumference in relation to incident vasomotor symptoms: the study of women’s health across the nation (SWAN). Menopause. 2017;24(1):9–26. doi:10.1097/GME.0000000000000723.
  • Anderson GS. Human morphology and temperature regulation. Int J Biometeorol. 1999;43(3):99–109. doi:10.1007/s004840050123.
  • Karim R, Dang HM, Hodis HN, et al. Association of hot flushes with ghrelin and adipokines in early versus late postmenopausal women. Menopause. 2020;27(5):512–518. doi:10.1097/GME.0000000000001508.
  • Hao G, Li W, Guo R, et al. Serum total adiponectin level and the risk of cardiovascular disease in general population: a meta-analysis of 17 prospective studies. Atherosclerosis. 2013;228(1):29–35. doi:10.1016/j.atherosclerosis.2013.02.018.
  • Huang WY, Chang CC, Chen DR, et al. Circulating leptin and adiponectin are associated with insulin resistance in healthy postmenopausal women with hot flashes. PLoS One. 2017;12(4):e0176430. doi:10.1371/journal.pone.0176430.
  • Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656–660. doi:10.1038/45230.
  • Thurston RC, Chang Y. Menopausal vasomotor symptoms and adiponectin among midlife women. Menopause. 2022;29(10):1145–1149. doi:10.1097/GME.0000000000002039.
  • Tang R, Fan Y, Luo M, et al. General and Central obesity are associated with increased severity of the VMS and sexual symptoms of menopause among chinese women: a longitudinal study. Front Endocrinol (Lausanne). 2022;13:814872. doi:10.3389/fendo.2022.814872.
  • Gao B, Huang Q, Lin YS, et al. Dose-dependent effect of estrogen suppresses the osteo-adipogenic transdifferentiation of osteoblasts via canonical wnt signaling pathway. PLoS One. 2014;9(6):e99137. doi:10.1371/journal.pone.0099137.
  • Zhao LJ, Jiang H, Papasian CJ, et al. Correlation of obesity and osteoporosis: effect of fat mass on the determination of osteoporosis. J Bone Miner Res. 2008;23(1):17–29. doi:10.1359/jbmr.070813.
  • Zhang Y, Pu J. The saturation effect of obesity on bone mineral density for older people: the NHANES 2017-2020. Front Endocrinol (Lausanne). 2022;13:883862. doi:10.3389/fendo.2022.883862.
  • Turcotte AF, O’Connor S, Morin SN, et al. Association between obesity and risk of fracture, bone mineral density and bone quality in adults: a systematic review and meta-analysis. PLoS One. 2021;16(6):e0252487. doi:10.1371/journal.pone.0252487.
  • Chen J, Zhu L, Yao X, et al. The association between abdominal obesity and femoral neck bone mineral density in older adults. J Orthop Surg Res. 2023;18(1):171. doi:10.1186/s13018-023-03654-3.
  • Kume S, Kato S, Yamagishi S, et al. Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone. J Bone Miner Res. 2005;20(9):1647–1658. doi:10.1359/JBMR.050514.
  • Gkastaris K, Goulis DG, Potoupnis M, et al. Obesity, osteoporosis and bone metabolism. J Musculoskelet Neuronal Interact. 2020;20(3):372–381.
  • Yang Y, Hu X, Zhang Q, et al. Diabetes mellitus and risk of falls in older adults: a systematic review and meta-analysis. Age Ageing. 2016;45(6):761–767. doi:10.1093/ageing/afw140.
  • Yazdany T, Jakus-Waldman S, Jeppson PC, et al. American urogynecologic society. American urogynecologic society systematic review: the impact of weight loss intervention on lower urinary tract symptoms and urinary incontinence in overweight and obese women. Female Pelvic Med Reconstr Surg. 2020;26(1):16–29. doi:10.1097/SPV.0000000000000802.
  • Fuselier A, Hanberry J, Margaret Lovin J, et al. Obesity and stress urinary incontinence: impact on pathophysiology and treatment. Curr Urol Rep. 2018;19(1):10. doi:10.1007/s11934-018-0762-7.
  • Shang X, Fu Y, Jin X, et al. Association of overweight, obesity and risk of urinary incontinence in Middle-aged and older women: a meta epidemiology study. Front Endocrinol (Lausanne). 2023;14:1220551. doi:10.3389/fendo.2023.1220551.
  • Gortan Cappellari G, Guillet C, Poggiogalle E, et al. Sarcopenic obesity research perspectives outlined by the sarcopenic obesity global leadership initiative (SOGLI) - Proceedings from the SOGLI consortium meeting in rome november 2022. Clin Nutr. 2023;42(5):687–699. doi:10.1016/j.clnu.2023.02.018.
  • Glaus J, Cui L, Hommer R, et al. Association between mood disorders and BMI/overweight using a family study approach. J Affect Disord. 2019;248:131–138. doi:10.1016/j.jad.2019.01.011.
  • Ali AM, Kunugi H. Royal jelly as an intelligent anti-Aging Agent-A focus on cognitive aging and Alzheimer’s disease: a review. Antioxidants (Basel). 2020;9(10):937. doi:10.3390/antiox9100937.
  • Elavsky S, Molenaar PCM, Gold CH, et al. Depressed mood but not fatigue mediate the relationship between physical activity and perceived stress in middle-aged women. Maturitas. 2009;71(3):287–293. doi:10.1016/j.maturitas.2011.12.011.
  • Abdelsamea GA, Amr M, Tolba AMN, et al. Impact of weight loss on sexual and psychological functions and quality of life in females with sexual dysfunction: a forgotten avenue. Front Psychol. 2023;14:1090256. doi:10.3389/fpsyg.2023.1090256.
  • Lyall DM, Celis-Morales C, Ward J, et al. Association of body mass index with cardiometabolic disease in the UK biobank: a Mendelian randomization study. JAMA Cardiol. 2017;2(8):882–889. doi:10.1001/jamacardio.2016.5804.
  • Rowland DL, McNabney SM, Mann AR. Sexual function, obesity, and weight loss in men and women. Sex Med Rev. 2017;5(3):323–338. doi:10.1016/j.sxmr.2017.03.006.
  • Sievert LL, Whitcomb BW, Verjee MA, et al. Limited evidence of a threshold effect for increasing adiposity on risk of symptoms at midlife. Menopause. 2022;29(12):1381–1387. doi:10.1097/GME.0000000000002074.
  • Nappi RE, Kroll R, Siddiqui E, et al. Global cross-sectional survey of women with vasomotor symptoms associated with menopause: prevalence and quality of life burden. Menopause. 2021;28(8):875–882. doi:10.1097/GME.0000000000001793.
  • Baber RJ, Panay N, Fenton A. 2016 IMS recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109–150. doi:10.3109/13697137.2015.1129166.
  • Lambrinoudaki I, Armeni E, Goulis D, et al. Menopause, wellbeing and health: a care pathway from the european menopause and andropause society. Maturitas. 2022;163:1–14. doi:10.1016/j.maturitas.2022.04.008.
  • “The 2022 hormone therapy position statement of the North American menopause society” advisory panel. The 2022 hormone therapy position statement of the North American menopause society. Menopause. 2022;29(7):767–794.
  • Palacios S, Stevenson JC, Schaudig K, et al. Hormone therapy for first-line management of menopausal symptoms: practical recommendations. Womens Health (Lond). 2019;15:1745506519864009. doi:10.1177/1745506519864009.
  • Bernasochi GB, Bell JR, Simpson ER, et al. Impact of estrogens on the regulation of white, beige, and brown adipose tissue depots. Compr Physiol. 2019;9(2):457–475.
  • Torres S, Fabersani E, Marquez A, et al. Adipose tissue inflammation and metabolic syndrome. The proactive role of probiotics. Eur J Nutr. 2019;58(1):27–43. doi:10.1007/s00394-018-1790-2.
  • Nappi RE. The 2022 hormone therapy position statement of the North American menopause society: no news is good news. Lancet Diabetes Endocrinol. 2022;10(12):832–834. doi:10.1016/S2213-8587(22)00285-6.
  • Trémollieres FA, Chabbert-Buffet N, Plu-Bureau G, et al. Management of postmenopausal women: collège national des gynécologues et obstétriciens français (CNGOF) and groupe d’Etude sur la ménopause et le vieillissement (GEMVi) clinical practice guidelines. Maturitas. 2022;163:62–81. doi:10.1016/j.maturitas.2022.05.008.
  • Gartlehner G, Patel SV, Reddy S, et al. Hormone therapy for the primary prevention of chronic conditions in postmenopausal persons: updated evidence report and systematic review for the US preventive services task force. JAMA. 2022;328(17):1747–1765. doi:10.1001/jama.2022.18324.
  • Canonico M, Oger E, Conard J, et al. EStrogen and THromboEmbolism risk (ESTHER) study group. Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER study. J Thromb Haemost. 2006;4(6):1259–1265. doi:10.1111/j.1538-7836.2006.01933.x.
  • Mendoza N, Ramírez I, de la Viuda E, et al. Eligibility criteria for menopausal hormone therapy (MHT): a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions. MHT eligibility criteria group. Maturitas. 2022;166:65–85. doi:10.1016/j.maturitas.2022.08.008.
  • Cushman M, Kuller LH, Prentice R, et al. Women’s health initiative investigators. Estrogen plus progestin and risk of venous thrombosis. JAMA. 2004;292(13):1573–1580. doi:10.1001/jama.292.13.1573.
  • Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019;364:k4810. doi:10.1136/bmj.k4810.
  • Wildman RP, Sowers MR. Adiposity and the menopausal transition. Obstet Gynecol Clin North Am. 2011;38(3):441–454. doi:10.1016/j.ogc.2011.05.003.
  • Al-Safi ZA, Polotsky AJ. Obesity and menopause. Best Pract Res Clin Obstet Gynaecol. 2015;29(4):548–553. doi:10.1016/j.bpobgyn.2014.12.002.
  • Saccomani S, Lui-Filho JF, Juliato CR, et al. Does obesity increase the risk of hot flashes among midlife women? A population-based study. Menopause. 2017;24(9):1065–1070. doi:10.1097/GME.0000000000000884.